CA2399550A1 - Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation - Google Patents
Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation Download PDFInfo
- Publication number
- CA2399550A1 CA2399550A1 CA002399550A CA2399550A CA2399550A1 CA 2399550 A1 CA2399550 A1 CA 2399550A1 CA 002399550 A CA002399550 A CA 002399550A CA 2399550 A CA2399550 A CA 2399550A CA 2399550 A1 CA2399550 A1 CA 2399550A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- subject
- immunomodulatory nucleic
- pyrimidine
- inflammatory bowel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
- A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides a method for ameliorating gastrointestinal inflammation, particularly chronic gastrointestinal inflammation such as inflammatory bowel disease (IBD), in a subject. In one embodiment, the metho d comprises administering an immunomodulatory nucleic acid to a subject suffering from or susceptible to gastrointestinal inflammation.
Description
METHOD
Claims (46)
1. A method for ameliorating gastrointestinal inflammation in a subject comprising:
administering to a subject suffering from gastrointestinal inflammation a formulation comprising an immunomodulatory nucleic acid to the subject, the immunomodulatory nucleic acid comprising the sequence 5'-CpG-3', said administering being in an amount effective to ameliorate a symptom of gastrointestinal inflammation in the subject;
wherein gastrointestinal inflammation is ameliorated in the subject.
administering to a subject suffering from gastrointestinal inflammation a formulation comprising an immunomodulatory nucleic acid to the subject, the immunomodulatory nucleic acid comprising the sequence 5'-CpG-3', said administering being in an amount effective to ameliorate a symptom of gastrointestinal inflammation in the subject;
wherein gastrointestinal inflammation is ameliorated in the subject.
2. The method of claim 1, wherein the immunomodulatory nucleic acid comprises the sequence 5'-Purine-Purine-[C]-[G]-Pyrimidine-Pyrimidine-3'.
3. The method of claim 1, wherein the immunomodulatory nucleic acid molecule comprises a CpG motif selected from the group consisting of:
a) 5'-Purine-TCG-Pyrimidine-Pyrimidine-3;
b) 5'-[TCG]n3', where n is any integer that is 1 or greater;
c) 5'-Purine-Purine-CG-Pyrimidine-Pyrimidine-CG-3'; and d) 5'-Purine-TCG-Pyrimidine-Pyrimidine-CG-3'
a) 5'-Purine-TCG-Pyrimidine-Pyrimidine-3;
b) 5'-[TCG]n3', where n is any integer that is 1 or greater;
c) 5'-Purine-Purine-CG-Pyrimidine-Pyrimidine-CG-3'; and d) 5'-Purine-TCG-Pyrimidine-Pyrimidine-CG-3'
4. The method of claim 1, wherein the immunomodulatory nucleic acid molecule is selected from the group consisting of an immunostimulatory oligodeoxyribonucleotide (ISS-ODN); an isolated bacterial genomic DNA and plasmid DNA comprising an immunomodulatory nucleic acid sequence.
5. The method of claim 1, wherein the immunomodulatory nucleic acid molecule comprises a sequence selected from the group consisting of: AACGCC, AACGCT, AACGTC, AACGTT, AGCGCC, AGCGCT, AGCGTC, AGCGTT, GACGCC, GACGCT, GACGTC, GACGTT, GGCGCC, GGCGCT, GGCGTC, GGCGTT, ATCGCC, ATCGCT, ATCGTC, ATCGTT, GTCGCC, GTCGCT, GTCGTC, GTCGTT, TCGTCG, TCGTCGTCG, AACGCCCG, AACGCTCG, AACGTCCG, AACGTTCG, AGCGCCCG, AGCGCTCG, AGCGTCCG, AGCGTTCG, GACGCCCG, GACGCTCG, GACGTCCG, GACGTTCG, GGCGCCCG, GGCGCTCG, GGCGTCCG, GGCGTTCG, ATCGCCCG, ATCGCTCG, ATCGTCCG, ATCGTTCG, GTCGCCCG, GTCGCTCG, GTCGTCCG, and GTCGTTCG.
6. The method of claim 4, wherein the immunomodulatory nucleic acid molecule comprises at least one sequence selected from the group consisting of AACGTT, aacgttcg, aacgtt, gtcgtt, and tcgtcg.
7. The method of claim 4, wherein the immunomodulatory nucleic acid molecule comprises at least one sequence selected from the group consisting of tgactgtgaacgttcgagatga (SEQ ID NO:1), tgactgtgaacgttagagatga (SEQ ID NO:5), tgactgtggtcgttagagatga (SEQ ID NO:9), tcgtcgtcgtcgtcgtcgtcgt (SEQ ID NO:10), and tgaaacgttcgcctgtcgttga (SEQ ID NO:11).
8. The method of claim 1, wherein the immunomodulatory nucleic acid is administered via a gastroenteral route.
9. The method of claim 1, wherein the gastroenteral route is oral, intranasal, intragastric or rectal
10. The method of claim 1, wherein the immunomodulatory nucleic acid is administered by a systemic route.
11. The method of claim 10, wherein the systemic route is intradermal, intramuscular, subcutaneous or intravenous.
12. The method of claim 1, wherein the immunomodulatory nucleic acid is administered by a mucosal route.
13. The method of claim 1, wherein the gastrointestinal inflammation is chronic gastrointestinal inflammation.
14. The method of claim 13, wherein the chronic gastrointestinal inflammation is caused by inflammatory bowel disease.
15. The method of claim 14, wherein the inflammatory bowel disease is ulcerative colitis.
16. The method of claim 14, wherein the inflammatory bowel disease is Crohn's disease.
17. The method of claim 14, wherein the immunomodulatory nucleic acid is administered in conjunction with a steroid or an antibody directed against tumor necrosis factor-.alpha. (TNF-.alpha.).
18. The method of claim 1, wherein the gastrointestinal inflammation is acute gastrointestinal inflammation.
19. A method for ameliorating inflammatory bowel disease in a subject comprising:
administering to a subject suffering from inflammatory bowel disease a formulation comprising an immunomodulatory nucleic acid to the subject, the immunomodulatory nucleic acid comprising the sequence 5'-Purine-Purine-[C]-[G]-Pyrimidine-Pyrimidine-3', said administering being in an amount effective to ameliorate a symptom of inflammatory bowel disease in the subject;
wherein inflammatory bowel disease is ameliorated in the subject.
administering to a subject suffering from inflammatory bowel disease a formulation comprising an immunomodulatory nucleic acid to the subject, the immunomodulatory nucleic acid comprising the sequence 5'-Purine-Purine-[C]-[G]-Pyrimidine-Pyrimidine-3', said administering being in an amount effective to ameliorate a symptom of inflammatory bowel disease in the subject;
wherein inflammatory bowel disease is ameliorated in the subject.
20. The method of claim 19, wherein said administering is by an intragastric route.
21. The method of claim 19, wherein said administering is by a subcutaneous route.
22. A method for ameliorating inflammatory bowel disease in a subject comprising:
administering to a subject suffering from inflammatory bowel disease a formulation comprising an immunomodulatory nucleic acid to the subject, the immunomodulatory nucleic acid comprising at least one sequence selected from the group consisting of tgactgtgaacgttcgagatga (SEQ ID NO:1), tgactgtgaacgttagagatga (SEQ ID NO:5), tgactgtggtcgttagagatga (SEQ ID NO:9), tcgtcgtcgtcgtcgtcgtcgt (SEA ID NO:10), and tgaaacgttcgcctgtcgttga (SEQ m NO:11), said administering being in an amount effective to ameliorate a symptom of inflammatory bowel disease in the subject;
administering to a subject suffering from inflammatory bowel disease a formulation comprising an immunomodulatory nucleic acid to the subject, the immunomodulatory nucleic acid comprising at least one sequence selected from the group consisting of tgactgtgaacgttcgagatga (SEQ ID NO:1), tgactgtgaacgttagagatga (SEQ ID NO:5), tgactgtggtcgttagagatga (SEQ ID NO:9), tcgtcgtcgtcgtcgtcgtcgt (SEA ID NO:10), and tgaaacgttcgcctgtcgttga (SEQ m NO:11), said administering being in an amount effective to ameliorate a symptom of inflammatory bowel disease in the subject;
23. A method for reducing inflammation caused by a gastrointestinal inflammatory disease in a subject, the method comprising:
administering to a subject suffering from gastrointestinal inflammatory disease a formulation comprising an immunomodulatory nucleic acid to the subject, the immunomodulatory nucleic acid comprising the sequence 5'-CpG-3', said administering being in an amount effective to reduce inflammation caused by gastrointestinal inflammatory disease in the subject;
wherein inflammation caused by gastrointestinal inflammatory disease is reduced in the subject.
administering to a subject suffering from gastrointestinal inflammatory disease a formulation comprising an immunomodulatory nucleic acid to the subject, the immunomodulatory nucleic acid comprising the sequence 5'-CpG-3', said administering being in an amount effective to reduce inflammation caused by gastrointestinal inflammatory disease in the subject;
wherein inflammation caused by gastrointestinal inflammatory disease is reduced in the subject.
24. The method of claim 23, wherein the immunomodulatory nucleic acid comprises the sequence 5'-Purine-Purine-[C]-[G]-Pyrimidine-Pyrimidine-3'.
25. The method of claim 23, wherein the immunomodulatory nucleic acid molecule comprises a CpG motif selected from the group consisting of:
a) 5'-Purine-TCG-Pyrimidine-Pyrimidine-3 ;
b) 5'-[TCG]n-3', where n is any integer that is 1 or greater;
c) 5'-Purine-Purine-CG-Pyrimidine-Pyrimidine-CG-3'; and d) 5'-Purine-TCG-Pyrimidine-Pyrimidine-CG-3'
a) 5'-Purine-TCG-Pyrimidine-Pyrimidine-3 ;
b) 5'-[TCG]n-3', where n is any integer that is 1 or greater;
c) 5'-Purine-Purine-CG-Pyrimidine-Pyrimidine-CG-3'; and d) 5'-Purine-TCG-Pyrimidine-Pyrimidine-CG-3'
26. The method of claim 23, wherein the immunomodulatory nucleic acid molecule is selected from the group consisting of an immunostimulatory oligodeoxyribonucleotide (ISS-ODN); an isolated, detoxified bacterial polynucleotide; bacterial genomic DNA;
and a plasmid DNA comprising an immunomodulatory nucleic acid.
and a plasmid DNA comprising an immunomodulatory nucleic acid.
27. The method of claim 23, wherein the immunomodulatory nucleic acid molecule comprises a sequence selected from the group consisting of AACGCC, AACGCT, AACGTC, AACGTT, AGCGCC, AGCGCT, AGCGTC, AGCGTT, GACGCC, GACGCT, GACGTC, GACGTT, GGCGCC, GGCGCT, GGCGTC, GGCGTT, ATCGCC, ATCGCT, ATCGTC, ATCGTT, GTCGCC, GTCGCT, GTCGTC, GTCGTT, TCGTCG, TCGTCGTCG, AACGCCCG, AACGCTCG, AACGTCCG, AACGTTCG, AGCGCCCG, AGCGCTCG, AGCGTCCG, AGCGTTCG, GACGCCCG, GACGCTCG, GACGTCCG, GACGTTCG, GGCGCCCG, GGCGCTCG, GGCGTCCG, GGCGTTCG, ATCGCCCG, ATCGCTCG, ATCGTCCG, ATCGTTCG, GTCGCCCG, GTCGCTCG, GTCGTCCG, and GTCGTTCG.
28. The method of claim 23, wherein the immunomodulatory nucleic acid molecule comprises the sequence at least one sequence selected from the group consisting of aacgtt, aacgttcg, aacgtt, gtcgtt, and tcgtcg.
29. The method of claim 23, wherein the immunomodulatory nucleic acid comprises at least one sequence selected from the group consisting of tgactgtgaacgttcgagatga (SEQ ID
NO:1), tgactgtgaacgttagagatga (SEQ ID NO:5), tgactgtggtcgttagagatga (SEQ ID
NO:9), tcgtcgtcgtcgtcgtcgtcgt (SEQ ID NO: 10), and tgaaacgttcgcctgtcgttga (SEQ ID
NO:11).
NO:1), tgactgtgaacgttagagatga (SEQ ID NO:5), tgactgtggtcgttagagatga (SEQ ID
NO:9), tcgtcgtcgtcgtcgtcgtcgt (SEQ ID NO: 10), and tgaaacgttcgcctgtcgttga (SEQ ID
NO:11).
30. The method of claim 23, wherein the immunomodulatory nucleic acid is administered via a gastroenteral route.
31. The method of claim 30, wherein the gastroenteral route is oral, intranasal, intragastric or rectal.
32. The method of claim 23, wherein the immunomodulatory nucleic acid is administered by a systemic route.
33. The method of claim 32, wherein the systemic route is intradermal, intramuscular, subcutaneous or intravenous.
34. The method of claim 23 wherein the immunomodulatory nucleic acid is administered by a mucosal route.
35. The method of claim 23, wherein the gastrointestinal inflammation is chronic gastrointestinal inflammation.
36. The method of claim 33, wherein the chronic gastrointestinal inflammation is caused by inflammatory bowel disease.
37. The method of claim 36, wherein the immunomodulatory nucleic acid is administered in conjunction with a steroid or an antibody directed against tumor necrosis factor-.alpha. (TNF-.alpha.).
38. The method of claim 35, wherein the chronic gastrointestinal inflammatory disease is ulcerative colitis.
39. The method of claim 35, wherein the chronic gastrointestinal inflammatory disease is Crohn's disease.
40. A method for reducing inflammation caused by inflammatory bowel disease in a subject comprising:
administering to a subject suffering from inflammatory bowel disease a formulation comprising an immunomodulatory nucleic acid to the subject, the immunomodulatory nucleic acid comprising the sequence 5'-Purine-Purine-[C]-[G]-Pyrimidine-Pyrimidine-3', said administering being in an amount effective to reduce inflammation caused by inflammatory bowel disease in the subject;
wherein inflammation caused by inflammatory bowel disease is reduced in the subject.
administering to a subject suffering from inflammatory bowel disease a formulation comprising an immunomodulatory nucleic acid to the subject, the immunomodulatory nucleic acid comprising the sequence 5'-Purine-Purine-[C]-[G]-Pyrimidine-Pyrimidine-3', said administering being in an amount effective to reduce inflammation caused by inflammatory bowel disease in the subject;
wherein inflammation caused by inflammatory bowel disease is reduced in the subject.
41. The method of claim 40, wherein said administering is by an intragastric route.
42. The method of claim 40, wherein said administering is by a subcutaneous route.
43. The method of claim 40, wherein the inflammatory bowel disease is ulcerative colitis.
44. The method of claim 40, wherein reduction of inflammation of ulcerative colitis further decreases the risk of colonic carcinoma.
45. The method of claim 43, wherein the inflammatory bowel disease is Crohn's disease.
46. A method for reducing inflammation of inflammatory bowel disease in a subject comprising:
administering to a subject suffering from inflammatory bowel disease a formulation comprising an immunomodulatory nucleic acid to the subject, the immunomodulatory nucleic acid comprising at least one sequence selected from the group consisting of tgactgtgaacgttcgagatga (SEQ ID NO:1), tgactgtgaacgttagagatga (SEQ ID NO:5), tgactgtggtcgttagagatga (SEQ ID NO:9), tcgtcgtcgtcgtcgtcgtcgt (SEQ ID NO:10), and tgaaacgttcgcctgtcgttga (SEQ ID NO:11), said administering being in an amount effective to reduce inflammation in the subject;
wherein inflammation caused by inflammatory bowel disease is reduced in the subject.
administering to a subject suffering from inflammatory bowel disease a formulation comprising an immunomodulatory nucleic acid to the subject, the immunomodulatory nucleic acid comprising at least one sequence selected from the group consisting of tgactgtgaacgttcgagatga (SEQ ID NO:1), tgactgtgaacgttagagatga (SEQ ID NO:5), tgactgtggtcgttagagatga (SEQ ID NO:9), tcgtcgtcgtcgtcgtcgtcgt (SEQ ID NO:10), and tgaaacgttcgcctgtcgttga (SEQ ID NO:11), said administering being in an amount effective to reduce inflammation in the subject;
wherein inflammation caused by inflammatory bowel disease is reduced in the subject.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18425600P | 2000-02-23 | 2000-02-23 | |
US60/184,256 | 2000-02-23 | ||
PCT/US2001/006034 WO2001062207A2 (en) | 2000-02-23 | 2001-02-22 | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2399550A1 true CA2399550A1 (en) | 2001-08-30 |
Family
ID=22676177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002399550A Abandoned CA2399550A1 (en) | 2000-02-23 | 2001-02-22 | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
Country Status (6)
Country | Link |
---|---|
US (2) | US6613751B2 (en) |
EP (1) | EP1259264A4 (en) |
AU (3) | AU2001241751B2 (en) |
CA (1) | CA2399550A1 (en) |
IL (1) | IL151345A0 (en) |
WO (1) | WO2001062207A2 (en) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030109469A1 (en) * | 1993-08-26 | 2003-06-12 | Carson Dennis A. | Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen |
US6727230B1 (en) * | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
EP0879284B1 (en) * | 1996-01-30 | 2009-07-29 | The Regents of The University of California | Gene expression vectors which generate an antigen specific immune response and methods of using the same |
US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
EP1733735B1 (en) * | 1998-05-22 | 2017-03-22 | Ottawa Hospital Research Institute | Methods and products for inducing mucosal immunity |
US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
EP1176966B1 (en) | 1999-04-12 | 2013-04-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Oligodeoxynucleotide and its use to induce an immune response |
ATE419869T1 (en) | 1999-08-19 | 2009-01-15 | Dynavax Tech Corp | METHOD FOR MODULATING AN IMMUNE RESPONSE USING IMMUNSTIMULATIVE SEQUENCES AND COMPOSITIONS THEREOF |
US7223398B1 (en) | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
ATE378348T1 (en) * | 2000-01-14 | 2007-11-15 | Us Health | OLIGODEOXYNUCLEOTIDES AND THEIR USE FOR INDUCING AN IMMUNE RESPONSE |
US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
US20040131628A1 (en) * | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
US20020107212A1 (en) * | 2000-03-10 | 2002-08-08 | Nest Gary Van | Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences |
US20030129251A1 (en) * | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
US7157437B2 (en) * | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
US20010046967A1 (en) * | 2000-03-10 | 2001-11-29 | Gary Van Nest | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide |
US20020098199A1 (en) * | 2000-03-10 | 2002-07-25 | Gary Van Nest | Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
US20020028784A1 (en) * | 2000-03-10 | 2002-03-07 | Nest Gary Van | Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences |
EP1292331A2 (en) * | 2000-06-07 | 2003-03-19 | Biosynexus Incorporated | Immunostimulatory rna/dna hybrid molecules |
US20030050268A1 (en) * | 2001-03-29 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases |
EP2423335B1 (en) | 2001-06-21 | 2014-05-14 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same |
US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
US20030133988A1 (en) * | 2001-08-07 | 2003-07-17 | Fearon Karen L. | Immunomodulatory compositions, formulations, and methods for use thereof |
AU2002361468A1 (en) * | 2001-08-14 | 2003-03-18 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human S | Method for rapid generation of mature dendritic cells |
ATE554169T1 (en) * | 2001-11-02 | 2012-05-15 | Giuliani Int Ltd | SMAD7 INHIBITORS FOR THE TREATMENT OF CNS DISEASES |
AU2002366710A1 (en) | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
JP4689268B2 (en) * | 2002-06-14 | 2011-05-25 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Methods for treating and preventing colitis for IL-13 and NK-T cells |
US20040053880A1 (en) * | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7569553B2 (en) * | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7576066B2 (en) * | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7807803B2 (en) * | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
NZ538628A (en) * | 2002-08-12 | 2008-06-30 | Dynavax Tech Corp | Immunomodulatory compositions, methods of making, and methods of use thereof |
US8263091B2 (en) * | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
US7105336B2 (en) * | 2002-10-07 | 2006-09-12 | Biogaia Ab | Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter |
ZA200503511B (en) | 2002-10-29 | 2006-10-25 | Coley Pharmaceutical Group Ltd | Use of CPG oligonucleotides in the treatment of hepatitis C virus infection |
US7758876B2 (en) * | 2002-11-01 | 2010-07-20 | The United States Of America As Represented By The Department Of Health And Human Services | Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides |
US7956043B2 (en) * | 2002-12-11 | 2011-06-07 | Coley Pharmaceutical Group, Inc. | 5′ CpG nucleic acids and methods of use |
EP1575977B1 (en) | 2002-12-23 | 2009-09-09 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
US8158768B2 (en) * | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
ITRM20030149A1 (en) | 2003-04-02 | 2004-10-03 | Giuliani Spa | ANTISENSE OLIGONUCLEOTIDES (ODN) FOR SMAD7 AND THEIR USE IN THE MEDICAL FIELD |
CN101454451A (en) | 2003-10-30 | 2009-06-10 | 科勒制药有限公司 | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
JP4817599B2 (en) * | 2003-12-25 | 2011-11-16 | 独立行政法人科学技術振興機構 | Immune activity enhancer and method for enhancing immune activity using the same |
WO2005072290A2 (en) * | 2004-01-23 | 2005-08-11 | Joslin Diabetes Center | Methods of treating, reducing, or preventing autoimmune conditions |
US20080008741A1 (en) * | 2004-02-03 | 2008-01-10 | Eyal Raz | Methods of Treating Irritable Bowel Syndrome |
US7560436B2 (en) | 2005-02-22 | 2009-07-14 | The Regents Of The University Of California | Methods of treating gastrointestinal inflammation |
CA2600036A1 (en) | 2005-03-04 | 2006-09-14 | Dynavax Technologies Corporation | Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients |
EP1877074B1 (en) | 2005-04-15 | 2013-03-27 | The Government of the United States of America, as represented by the Secretary of Health and Human Services | Treatment and prevention of inflammatory bowel disease involving il-13 and nkt cells |
AU2006335883B2 (en) * | 2006-01-20 | 2011-04-28 | Morinaga Milk Industry Co., Ltd. | Pharmaceutical composition, food or drink, or feed for intestinal disease |
CN105853394A (en) * | 2006-03-30 | 2016-08-17 | 恩根尼公司 | Non-viral compositions and methods for transfecting gut cells in vivo |
WO2008121386A2 (en) * | 2007-03-30 | 2008-10-09 | Amgen Inc. | Calcimimetic compounds for use in the treatment of bowel disorders |
US8518903B2 (en) | 2007-04-19 | 2013-08-27 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of toll-like receptor-9 agonists |
WO2008131074A1 (en) * | 2007-04-19 | 2008-10-30 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders |
CN101820908A (en) | 2007-10-09 | 2010-09-01 | 科利制药公司 | The immune stimulatory oligonucleotide analogs that comprises modified sugar moieties |
US10668092B2 (en) | 2010-09-24 | 2020-06-02 | The John Hopkins University | Compositions and methods for treatment of inflammatory disorders |
US9072760B2 (en) | 2010-09-24 | 2015-07-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders |
WO2012088425A2 (en) | 2010-12-22 | 2012-06-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease |
AR091569A1 (en) * | 2012-06-28 | 2015-02-11 | Intervet Int Bv | TOLL TYPE RECEIVERS |
US9562066B2 (en) | 2012-09-25 | 2017-02-07 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Oral therapy of necrotizing enterocolitis |
EP3223803A1 (en) * | 2014-11-24 | 2017-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of ox1r antagonists for the treatment of inflammatory bowel diseases |
MA41271A (en) * | 2014-12-26 | 2017-10-31 | Celgene Alpine Invest Company Ii Llc | METHODS OF USE OF OLIGONUCLEOTIDES ANTISENS TARGETING SMAD7 |
US20200281950A1 (en) * | 2015-12-28 | 2020-09-10 | Mb Biotech Ltd. | Liposomes for treatment of an autoimmune disease |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5716615A (en) | 1992-02-10 | 1998-02-10 | Renata Maria Anna Cavaliere Vesely | Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use |
CA2194761C (en) | 1994-07-15 | 2006-12-19 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
AU6280596A (en) * | 1995-06-15 | 1997-01-15 | University Of Victoria Innovation And Development Corporation | Mycobacterium tuberculosis dna sequences encoding immunostimlatory peptides |
WO1998037919A1 (en) * | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
ES2284247T3 (en) | 1998-04-03 | 2007-11-01 | University Of Iowa Research Foundation | METHODS AND PRODUCTS TO STIMULATE THE IMMUNITY SYSTEM USING OLIGONUCLEOTIDES AND IMMUNOTHERAPEUTIC CYTOQUINS. |
US20030013668A1 (en) * | 1998-07-07 | 2003-01-16 | Dange Veerapanane Ph.D | Antisense oligonucleotides targeted to il-15 |
AP1775A (en) | 1999-09-25 | 2007-08-28 | Univ Iowa Res Found | Immunostimulatory nucleic acids. |
MXPA02003059A (en) | 1999-09-27 | 2002-09-30 | Univ Iowa Res Found | Methods related to immunostimulatory nucleic acid induced interferon. |
-
2001
- 2001-02-22 EP EP01913036A patent/EP1259264A4/en not_active Withdrawn
- 2001-02-22 WO PCT/US2001/006034 patent/WO2001062207A2/en active IP Right Grant
- 2001-02-22 AU AU2001241751A patent/AU2001241751B2/en not_active Ceased
- 2001-02-22 CA CA002399550A patent/CA2399550A1/en not_active Abandoned
- 2001-02-22 US US09/791,500 patent/US6613751B2/en not_active Expired - Fee Related
- 2001-02-22 AU AU4175101A patent/AU4175101A/en active Pending
- 2001-02-22 IL IL15134501A patent/IL151345A0/en unknown
-
2003
- 2003-04-11 US US10/412,151 patent/US7485627B2/en not_active Expired - Fee Related
-
2005
- 2005-11-25 AU AU2005237172A patent/AU2005237172A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001062207A2 (en) | 2001-08-30 |
US7485627B2 (en) | 2009-02-03 |
EP1259264A4 (en) | 2005-08-31 |
US20030176389A1 (en) | 2003-09-18 |
US6613751B2 (en) | 2003-09-02 |
WO2001062207A3 (en) | 2001-12-20 |
IL151345A0 (en) | 2003-04-10 |
US20020042387A1 (en) | 2002-04-11 |
EP1259264A2 (en) | 2002-11-27 |
AU2005237172A1 (en) | 2005-12-15 |
AU2001241751B2 (en) | 2005-09-01 |
AU4175101A (en) | 2001-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2399550A1 (en) | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation | |
JP2002500159A5 (en) | ||
O'hagan | The intestinal uptake of particles and the implications for drug and antigen delivery. | |
HK1191567A1 (en) | Multivalent pneumococcal polysaccharide protein conjugate composition | |
MX2013006539A (en) | Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions. | |
MX2019008863A (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition. | |
MY159984A (en) | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition | |
PL1631264T3 (en) | Immunogenic compositions based on biodegradable microparticles comprising a diphtheria- and a tetanus toxoid | |
MX2009006548A (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition. | |
MX2009013949A (en) | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates. | |
WO2004087153A3 (en) | Use of organic compounds for immunopotentiation | |
EA200801367A1 (en) | VACCINE CONTAINING CONJUGATES OF CAPSULAR POLYSACCHARIDES STREPTOCOCCUS PNEUMONIAE | |
WO2004053056A3 (en) | Nanoparticle-based vaccine delivery system containing adjuvant | |
MX2009007144A (en) | Antifolate agent combinations in the treatment of cancer. | |
MX2009011312A (en) | Vaccination regimen for b-cell vaccines. | |
Kim et al. | Development of lymphocytic gastritis with recurrent Helicobacter pylori infection. | |
Kim et al. | Enhanced Cancer Immunotherapy by In situ Nanomicelle-generating Dissolving Microneedles | |
Tran et al. | Clinical Characteristics, Endoscopic Images and Histopathology of Colorectal Cancer at 108 Military Central Hospital from 2018 to 2019. | |
Arfi et al. | Carcinome cuniculatum: une tumeur orale inhabituelle | |
Skwarczynski et al. | Polymerized Amino Acids as a Self-Adjuvanting Delivery System for Vaccine against Group A Streptococcus | |
Khaki Najafabadi et al. | Magnetic Drug Delivery of Xanthohumol to Adipocytes Using Ultrasmall Superparamagnetic Iron Oxide Nanoparticles. | |
Rustamov | Elaboration of optimal Helicobacter pylori eradication regimens for patients with duodenal ulcer | |
Herrero et al. | Síndrome alcohólico fetal. Criterios diagnósticos. Hallazgos en 13 casos estudiados | |
Park et al. | Enhanced mucosal and systemic immune responses by mucosally administered hepatitis B surface antigen: effects of vaccine delivery vehicles and adjuvants | |
ICHINOKAWA et al. | A case of a rectal carcinoid tumor with solitary recurrence to the right lateral lymph node performed trans-sacral extirpation after systemic chemotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |